ArticleThe international journal of cardiovascular imaging2025
Resting coronary flow and long-term clinical outcomes in dilated cardiomyopathy.
Article in The international journal of cardiovascular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compensatory high resting coronary flow (rCF) is a major determinant of low coronary flow reserve in patients with dilated cardiomyopathy (DCM). We sought to assess if angiography-derived rCF was associated with left ventricle reverse remodeling (LVRR) and clinical outcomes in DCM. Angiography-derived rCF was derived based on TIMI frame count and validated using invasive continuous thermodilution absolute flow (n = 48). The association between rCF and clinical outcomes was evaluated in a prospectively enrolled cohort of patients with DCM who underwent coronary angiography to rule out coronary disease (n = 110). The primary endpoint was the composite of all-cause death, rehospitalization for heart failure, relevant ventricular arrhythmias, appropriate implanted cardiac defibrillator intervention, and cardiac transplantation or left ventricular assist device implantation. LVRR was evaluated after at least 12 months of guidelines-directed medical therapy (GDMT). rCF was significantly correlated with thermodilution-derived resting coronary perfusion (rho = 0.411, p = 0.004). High rCF (≥ 2.32) was associated with impaired microvascular resistance reserve (AUC 0.721; 95% CI 0.572 to 0.870, p = 0.004). Among 110 patients of the prognostic cohort, 15 patients (13.6%) met the primary endpoint. rCF was higher in patients without LVRR (2.14 [1.67 to 3.0] vs. 1.87 [1.36 to 2.50], p = 0.036) and in those who met the primary endpoint (3.0 [1.87 to 3.75] vs. 1.87 [1.36 to 2.50], p = 0.004). Patients with rCF ≥ 2.32 had a higher rate of events compared with patients with preserved rCF (27.5% vs. 5.7%, log-rank p = 0.007; aHR 4.143 [95% CI 1.315 to 13.059], p = 0.015). In DCM patients, high rCF was associated with a reduced rate of LVRR after GDMT and adverse clinical outcomes at long-term follow-up.
Indexed as
Identifiers
40439757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.